Journal of Computer-Aided Molecular Design

, Volume 26, Issue 3, pp 267–277 | Cite as

Development of energetic pharmacophore for the designing of 1,2,3,4-tetrahydropyrimidine derivatives as selective cyclooxygenase-2 inhibitors

  • Deepak Lokwani
  • Reecha Shah
  • Santosh Mokale
  • Padma Shastry
  • Devanand Shinde
Article

Abstract

We present here the Energetic pharmacophore model representing complementary features of the 1,2,3,4-tetrahydropyrimidine for selective cyclooxygenase-2 (COX-2) inhibition. For the development of pharmacophore hypothesis, a total of 43 previously reported compounds were docked on active site of COX-2 enzyme. The generated pharmacophore features were ranked using energetic terms of Glide XP docking for 1,2,3,4-tetrahydropyrimidine scaffold to optimize its structure requirement for COX-2 inhibition. The thirty new 4,5,6-triphenyl-1,2,3,4-tetrahydropyrimidine derivatives were synthesized and assessed for selective COX-2 inhibitory activity. Two compounds 4B1 and 4B11 were found to be potent and selective COX-2 inhibitors. The molecular docking studies revealed that the newly synthesized compounds can be docked into COX-2 binding site and also provide the molecular basis for their activity.

Keywords

E-pharmacophore Docking 1,2,3,4-tetrahydropyrimidine COX-2 Glide XP 

Notes

Acknowledgments

The authors are thankful to University Grant Commission (UGC), New Delhi for financial assistance (No.F.37-145/2009). The authors thank the Head, Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad 431 004 (MS), India for providing the laboratory facility. Ms. Reecha Shah is a research assistant in ICMR funded project (No.53/6/2010-BMS).

Supplementary material

10822_2011_9540_MOESM1_ESM.doc (592 kb)
Supporting Materials (DOC 592 kb)

References

  1. 1.
    Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013–12017CrossRefGoogle Scholar
  2. 2.
    Tanabe T, Tohnai N (2002) Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68–69:95–114CrossRefGoogle Scholar
  3. 3.
    Sakamoto C, Soen S (2011) Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion 83:108–123CrossRefGoogle Scholar
  4. 4.
    Lanas A (2010) A review of the gastrointestinal safety data—a gastroenterologist’s perspective. Rheumatology 49:ii3–ii10Google Scholar
  5. 5.
    Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102CrossRefGoogle Scholar
  6. 6.
    Couzin J (2004) Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306:384–385CrossRefGoogle Scholar
  7. 7.
    García Rodríguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628–1636CrossRefGoogle Scholar
  8. 8.
    Goodson NJ, Brookhart AM, Symmons DPM, Silman AJ, Solomon DH (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 8:367–372CrossRefGoogle Scholar
  9. 9.
    Reddy LR, Corey EJ (2005) Facile air oxidation of the conjugate base of rofecoxib (VioxxTM), a possible contributor to chronic human toxicity. Tetrahedron Lett 46:927–929CrossRefGoogle Scholar
  10. 10.
    Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: Randomized controlled trial. Lancet 364:675–684CrossRefGoogle Scholar
  11. 11.
    Fitzgerald GA (2004) Coxibs and cardiovascular disease. New Engl J Med 351:1709–1711CrossRefGoogle Scholar
  12. 12.
    Li Y, Slatter JG, Zhang Z, Li Y, Doss GA, Braun MP, Stearns RA, Dean DC, Baillie TA, Tang W (2008) In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab Dispos 36:469–473CrossRefGoogle Scholar
  13. 13.
    Orjales A, Mosquera R, López B, Olivera R, Labeaga L, Núñez MT (2008) Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorg Med Chem 16:2183–2199CrossRefGoogle Scholar
  14. 14.
    Mohamed MS, Awad SM, Sayed AI (2010) Synthesis of certain pyrimidine derivatives as antimicrobial agents and anti-inflammatory agents. Molecules 15:1882–1890CrossRefGoogle Scholar
  15. 15.
    Alam O, Khan SA, Siddiqui N, Ahsan W, Verma SP, Gilani SJ (2010) Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: Synthesis and pharmacological evaluation. Eur J Med Chem 45:5113–5119CrossRefGoogle Scholar
  16. 16.
    Tale RH, Rodge AH, Hatnapure GD, Keche AP (2011) The novel 3,4-dihydropyrimidin-2(1H)-one urea derivatives of N-aryl urea: synthesis, anti-inflammatory, antibacterial and antifungal activity evaluation. Bioorg Med Chem Lett 21:4648–4651CrossRefGoogle Scholar
  17. 17.
    Mokale SN, Shinde SS, Elgire RD, Sangshetti JN, Shinde DB (2010) Synthesis and anti-inflammatory activity of some 3-(4,6-disubtituted-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl) propanoic acid derivatives. Bioorg Med Chem Lett 20:4424–4426CrossRefGoogle Scholar
  18. 18.
    Bahekar SS, Shinde DB (2004) Synthesis and anti-inflammatory activity of some [4,6-(4-substituted aryl)-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-acetic acid derivatives. Bioorg Med Chem Lett 14:1733–1736CrossRefGoogle Scholar
  19. 19.
    Bahekar SS, Shinde DB (2003) Synthesis and anti-inflammatory activity of some (2-amino-6-(4-substituted aryl)-4-(4-substitutedphenyl)-1,6-dihydropyrimidine-5-yl)-acetic acid derivatives. Acta Pharm 53:223–229Google Scholar
  20. 20.
    Durdagi S, Duff HJ, Noskov Su (2011) Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J Chem Inf Model 51:463–474CrossRefGoogle Scholar
  21. 21.
    Chopra M, Gupta R, Gupta S, Saluja D (2008) Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst. J Mol Model 14:1087–1099CrossRefGoogle Scholar
  22. 22.
    Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196CrossRefGoogle Scholar
  23. 23.
    Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 49:2356–2368CrossRefGoogle Scholar
  24. 24.
    Loving K, Salam NK, Sherman W (2009) Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23:541–554CrossRefGoogle Scholar
  25. 25.
    Ali AM, Saber GE, Mahfouz NM, EI-Gendy MA, Radwan AA, Hamid MA (2007) Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors. Arch Pharm Res 30:1186–1204CrossRefGoogle Scholar
  26. 26.
    Garavito RM (1999) The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1441:278–287Google Scholar
  27. 27.
    Charlier C, Michaux C (2003) Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 38:645–659CrossRefGoogle Scholar
  28. 28.
    Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8:127–134CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Deepak Lokwani
    • 1
  • Reecha Shah
    • 2
  • Santosh Mokale
    • 3
  • Padma Shastry
    • 2
  • Devanand Shinde
    • 1
  1. 1.Department of Chemical TechnologyDr. Babasaheb Ambedkar Marathwada UniversityAurangabadIndia
  2. 2.National Centre for Cell Science (NCCS)Ganeshkhind, PuneIndia
  3. 3.Y.B. Chavan College of PharmacyAurangabadIndia

Personalised recommendations